{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:32:46Z","timestamp":1777923166383,"version":"3.51.4"},"reference-count":36,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T00:00:00Z","timestamp":1380240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:p>\n                    Objective: To review the pharmacology, pharmacokinetics, safety, and efficacy of avanafil and evaluate relevant clinical trial data. Data Sources: A MEDLINE, International Pharmaceutical Abstracts, ClinicalTrials.gov, and Google Scholar searches (1966 to July 2013) were conducted using the key words: avanafil, erectile dysfunction, and phosphodiesterase type 5 (PDE\n                    <jats:sub>5<\/jats:sub>\n                    ) inhibitor. Study Selection and Data Extraction: Articles evaluating avanafil for erectile dysfunction (ED) published in English and using human subjects were selected. Five clinical trials were identified. References cited in identified articles were used for additional citations. Data Synthesis: Avanafil is a highly selective PDE\n                    <jats:sub>5<\/jats:sub>\n                    inhibitor that is a competitive antagonist of cyclic guanosine monophosphate. Specifically, avanafil has a high ratio of inhibiting PDE\n                    <jats:sub>5<\/jats:sub>\n                    as compared with other PDE subtypes allowing for the drug to be used for ED while minimizing adverse effects. Absorption occurs quickly following oral administration with a median T\n                    <jats:sub>max<\/jats:sub>\n                    of 30 to 45 minutes and a terminal elimination half-life of 5 hours. Additionally, it is predominantly metabolized by cytochrome P450 3A4. As such, avanafil should not be co-administered with strong cytochrome P450 3A4 inhibitors. Dosage adjustments are not warranted based on renal function, hepatic function, age or gender. Five clinical trials suggest that avanafil 100 and 200 mg doses are effective in improving the Sexual Encounter Profile and the Erectile Function Domain scores among men as part of the International Index of Erectile Function. A network meta-analysis comparing the PDE\n                    <jats:sub>5<\/jats:sub>\n                    inhibitors revealed avanafil was less effective on Global Assessment Questionnaire question 1 while safety data indicated no major differences among the different PDE\n                    <jats:sub>5<\/jats:sub>\n                    inhibitors. The most common adverse effects reported from the clinical trials associated with avanafil were headache, flushing, nasal congestion, nasopharyngitis, sinusitis, and dyspepsia. Conclusions: Avanafil is a potent PDE\n                    <jats:sub>5<\/jats:sub>\n                    inhibitor and is an effective treatment option for ED.\n                  <\/jats:p>","DOI":"10.1177\/1060028013501989","type":"journal-article","created":{"date-parts":[[2014,7,15]],"date-time":"2014-07-15T13:56:59Z","timestamp":1405432619000},"page":"1312-1320","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":36,"title":["Avanafil for Erectile Dysfunction"],"prefix":"10.1177","volume":"47","author":[{"given":"Jeffrey A.","family":"Kyle","sequence":"first","affiliation":[{"name":"Samford University, Birmingham, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana A.","family":"Brown","sequence":"additional","affiliation":[{"name":"Palm Beach Atlantic University, West Palm Beach, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerame K.","family":"Hill","sequence":"additional","affiliation":[{"name":"Samford University, Birmingham, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,9,27]]},"reference":[{"key":"bibr1-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.22.3.0430"},{"key":"bibr2-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03510010089036"},{"key":"bibr3-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67900-1"},{"key":"bibr4-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1016\/S0094-0143(21)00690-X"},{"key":"bibr5-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1999.00142.x"},{"key":"bibr6-1060028013501989","unstructured":"IMS Institute for Healthcare Informatics. The use of medicines in the United States: review of 2011. IMS Institute for Healthcare Informatics Web site. http:\/\/www.imshealth.com\/ims\/Global\/Content\/Insights\/IMS%20Institute%20for%20Healthcare%20Informatics\/IHII_Medicines_in_U.S_Report_2011.pdf. Accessed June 23, 2012."},{"key":"bibr7-1060028013501989","unstructured":"Pharmacy Times. Top 200 prescription drugs of 2011. http:\/\/www.pharmacytimes.com\/publications\/issue\/2012\/July2012\/Top-200-Drugs-of-2011. Accessed August 11, 2012."},{"key":"bibr8-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000164463.19239.19"},{"key":"bibr9-1060028013501989","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-9-200911030-00151"},{"key":"bibr10-1060028013501989","doi-asserted-by":"publisher","DOI":"10.4158\/EP.9.1.77"},{"key":"bibr11-1060028013501989","unstructured":"US Food and Drug Administration. FDA news release. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm302140.htm. Accessed August 20, 2012."},{"key":"bibr12-1060028013501989","unstructured":"Strendra (avanafil) [product information]. Mountain View, CA: Vivus, Inc, April 2012."},{"key":"bibr13-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2010.06.011"},{"key":"bibr14-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2011.614435"},{"key":"bibr15-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.03.115"},{"key":"bibr16-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2012.02822.x"},{"key":"bibr17-1060028013501989","volume-title":"Presented at: 15th Congress of the European Society for Sexual Medicine","author":"Wang R"},{"key":"bibr18-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2010.518955"},{"key":"bibr19-1060028013501989","volume-title":"Presented at: 15th Congress of the European Society for Sexual Medicine","author":"Allison M"},{"key":"bibr20-1060028013501989","volume-title":"Presented at: American Urology Association Annual Meeting","author":"Hellstrom WJG"},{"key":"bibr21-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901522"},{"key":"bibr22-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1177\/1756287212466282"},{"key":"bibr23-1060028013501989","unstructured":"Viagra (sildenafil citrate) [product information]. New York, NY: Pfizer Labs, Inc, January 2010."},{"key":"bibr24-1060028013501989","unstructured":"Cialis (tadalafil) [product information]. Indianapolis, IN: Eli Lilly and Company, October 2011."},{"key":"bibr25-1060028013501989","unstructured":"Levitra (vardenafil HCl) [product information]. Wayne, NJ: Bayer HealthCare Pharmaceuticals, Inc, April 2011."},{"key":"bibr26-1060028013501989","doi-asserted-by":"crossref","unstructured":"Red Book Online. In: Micromedex 2.0. Greenwood Village, CO: Truven Health Analytics, expires December 31, 2013. http:\/\/www.redbook.com\/redbook\/index.html. Accessed July 10, 2013.","DOI":"10.12968\/eqhe.2013.1.10.31"},{"key":"bibr27-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2011.02629.x"},{"key":"bibr28-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11095.x"},{"key":"bibr29-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.06.016"},{"key":"bibr30-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.11.177"},{"key":"bibr31-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12065"},{"key":"bibr32-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00238-0"},{"key":"bibr33-1060028013501989","unstructured":"Agency for Healthcare Research and Quality. Diagnosis and treatment of erectile dysfunction. http:\/\/www.ahrq.gov\/clinic\/tp\/erecdystp.htm. Accessed October 1, 2012."},{"key":"bibr34-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijir.3901227"},{"key":"bibr35-1060028013501989","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.01.012"},{"key":"bibr36-1060028013501989","first-page":"435","volume":"5","author":"Alwaal A","year":"2011","journal-title":"Drug Des Dev Ther"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028013501989","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028013501989","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028013501989","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:23Z","timestamp":1777374863000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028013501989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,27]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1177\/1060028013501989"],"URL":"https:\/\/doi.org\/10.1177\/1060028013501989","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,27]]}}}